White blood cell count predicts response to lung cancer immunotherapy

White blood cell counts can predict whether or not lung cancer patients will benefit from immunotherapy, according to research presented at the European Lung Cancer Conference (ELCC).

"Immune checkpoint inhibitors such as and pembrolizumab significantly improve overall survival in some - but not all - patients with non-small cell lung cancer (NSCLC)," said lead author Dr Marcello Tiseo, Coordinator of DMT Thoracic Oncology, University Hospital of Parma, Italy. "Researchers are looking for a predictive biomarker to select patients that will benefit from this treatment to avoid unnecessary toxicity and a waste of resources in patients who will not respond."

He continued: "PD-L1 expression in a biopsy of tumour tissue is used to select patients but it is not completely accurate, possibly because it does not reflect the evolving immune response. Biomarkers in the blood are easier to obtain and may be better indicators of ."

This study assessed the ability of white blood cell counts to predict whether responded to treatment with nivolumab. The study included 54 patients with NSCLC who received nivolumab at a dose of 3 mg/kg every 14 days. White blood cell counts were performed at baseline, after two nivolumab cycles, and after four nivolumab cycles. The researchers compared white blood cell counts between responders and non-responders to nivolumab.

The researchers found that white blood cell counts at baseline and during therapy predicted whether patients would respond to nivolumab treatment. A greater number and concentration of natural killer cells at baseline was associated with response to nivolumab, as was an increase in the number of natural killer cells during treatment. Responders to nivolumab also had a greater number and concentration of CD8 positive T cells that expressed PD-1.

Tiseo said: "The number and function of and the frequency of PD-1 expression in CD8 positive T cells could be predictive biomarkers for nivolumab treatment in advanced NSCLC. The identification of a panel of predictive biomarkers would enable the early identification of patients most likely to benefit from anti-PD-1 and anti-PD-L1 treatment."

Commenting on the findings, Dr Stefan Zimmermann, Senior Consultant, Medical Oncology Department, HFR - Hôpital Cantonal, Fribourg, Switzerland, said: "In the current era of precision medicine and increasing healthcare costs we urgently need proper predictive biomarkers to select patients that will benefit from a specific therapy."

He continued: "This study found that baseline levels of certain do have a role in predicting response to immunotherapy in patients with . These new factors should be investigated in future clinical trials, together with tumour PD-L1 expression and other markers that constitute the cancer immunogram predict whether or not will benefit from treatment."


Explore further

Some head and neck cancer patients benefit from continued checkpoint inhibitor treatment

More information: Abstract 30PD - 'Circulating immune-profile as predictor of outcome in NSCLC patients treated with Nivolumab' will be presented by Dr Marcello Tiseo during the Poster Discussion session 'Epidemiology and innovations in biomarker development' on Saturday, 6 May, 16:45 (CEST).
Citation: White blood cell count predicts response to lung cancer immunotherapy (2017, May 4) retrieved 16 October 2019 from https://medicalxpress.com/news/2017-05-white-blood-cell-response-lung.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
0 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more